STERIS plc

STERIS plc(STE)股票分析

$222.660

-1.648 (-0.74%)收盤時

Loading chart…
最高
226.715
開盤
225.370
成交量加權均價
223.49
成交量
601.45K
市值
21.40B
最低
221.105
成交金額
134.42M
企業價值/稅息折舊攤銷前利潤(TTM)
13.11

STERIS Plc is a provider of products and services that support patient care with an emphasis on infection prevention. Its segments include Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. Its Healthcare segment provides a comprehensive offering for healthcare providers worldwide, focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. AST segment supports medical device and pharmaceutical manufacturers through a global network of contract sterilization and laboratory testing facilities, and integrated sterilization equipment and control systems. Its Life Sciences segment provides a comprehensive offering of products and services designed to support biopharmaceutical and medical device manufacturing facilities, particularly those focused on aseptic manufacturing. Its portfolio includes a full suite of consumable products, equipment maintenance, specialty services, and capital equipment.

AI 分析 of STERIS plc (STE)

買進

STERIS plc is a good buy right now due to its current price of $222.66, which is below the analyst price target of $275 from UBS, indicating significant upside potential. Additionally, the company has shown a strong gross margin of 43.89% in the latest quarter, reflecting solid profitability. However, the main risk is the recent decline in free cash flow, which dropped to $279.6 million from $326.5 million year-over-year, highlighting potential cash management challenges.

分析師評級(8)

買進
6 買進
2 持有
0 賣出
目前: 222.66
最低
—
平均
—
最高
—

UBS

2026-07-28

目標價

$275

買進

KeyBanc

2026-05-13

目標價

$269

增持

Morgan Stanley

2026-01-08

目標價

—

Equal Weight

JPMorgan

2025-12-05

目標價

—

中性

KeyBanc

2025-07-22

目標價

$288

增持

估值指標

STERIS plc(STE)目前預期本益比為 19.16,5 年平均預期本益比為 23.78。

預期本益比

低估
5 年均值 P/E
23.78
目前P/E
19.16
高估
26.52
低估
21.03

預期 EV/EBITDA

低估
5 年均值 EV/EBITDA
16.17
目前EV/EBITDA
13.11
高估
18.55
低估
13.78

預期股價營收比

低估
5 年均值 P/S
3.91
目前P/S
3.23
高估
4.38
低估
3.45

Alphio AI 對 STE 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%STE

$245.24

情境價格

基

基準

基準 · 50%STE

$207.79

情境價格

悲

悲觀

悲觀 · 25%STE

$150.35

情境價格

持有 STE 的大戶

G

Generation Investment Management LLP

+ 持有STE

+10.11%

3個月報酬率

C

Campbell & Company, LP

+ 持有STE

+9.49%

3個月報酬率

A

Addenda Capital Inc.

+ 持有STE

+5.98%

3個月報酬率

S

Sustainable Growth Advisers, LP

+ 持有STE

+4.45%

3個月報酬率

W

Williams Jones Wealth Management, LLC

+ 持有STE

+3.59%

3個月報酬率

C

Colonial Trust Advisors, Inc.

+ 持有STE

+3.47%

3個月報酬率

事件時間軸

2026-10-12 (ET)

15:00:00

Steris Acquires Xodus Medical

2026-08-05 (ET)

09:31:00

Steris Invests $600M to Build Manufacturing Center in North Carolina

2026-07-30 (ET)

17:00:00

Steris Announces Quarterly Dividend of 69 Cents per Share

2026-05-11 (ET)

16:40:00

Company Reports Q4 Revenue of $1.6B

16:40:00

Sees FY27 Revenue Growth 7%-8% from $5.9B

資訊

STE 常見問題 —— 由 Alphio AI 解答

STERIS Plc is a provider of products and services that support patient care with an emphasis on infection prevention. Its segments include Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. Its Healthcare segment provides a comprehensive offering for healthcare providers worldwide, focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. AST segment supports medical device and pharmaceutical manufacturers through a global network of contract sterilization and laboratory testing facilities, and integrated sterilization equipment and control systems. Its Life Sciences segment provides a comprehensive offering of products and services designed to support biopharmaceutical and medical device manufacturing facilities, particularly those focused on aseptic manufacturing. Its portfolio includes a full suite of consumable products, equipment maintenance, specialty services, and capital equipment. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUP industry).

STERIS plc is a good buy right now due to its current price of $222.66, which is below the analyst price target of $275 from UBS, indicating significant upside potential. Additionally, the company has shown a strong gross margin of 43.89% in the latest quarter, reflecting solid profitability. However, the main risk is the recent decline in free cash flow, which dropped to $279.6 million from $326.5 million year-over-year, highlighting potential cash management challenges.

8 analysts cover STE: 6 rate it Buy, 2 Hold and 0 Sell.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易